Deutsche Bank Injects Rs 5,113 Cr into India Operations

By By Rediff Money Desk, Mumbai
Nov 06, 2024 11:08
Deutsche Bank has infused Rs 5,113 crore into its India operations, the largest capital allocation in recent years, to expand across business lines.
Mumbai, Nov 6 (PTI) German lender Deutsche Bank on Wednesday announced that it has infused an additional capital of Rs 5,113 crore into its India operations.

This is the largest capital allocation to India in recent years and will be used for expanding across business lines, including corporate banking, investment banking and private banking, according to a Deutsche Bank's statement.

The lender has been present in India for the last 45 years and the balance sheet size stood at Rs 1.45 lakh crore as of March 31, 2024, making it one of the largest foreign banks in the country. It has 17 branches in the country.

The fresh infusion marks a 33 per cent jump in the capital buffer over the 2023 levels and increases the regulatory capital of Deutsche Bank AG India branches to nearly Rs 30,000 crore, the statement said, adding that the same has grown three times in the last decade.

"India is well positioned to benefit substantially from many of today's most important trends reshaped supply chains, digitisation of industries, increased geopolitical frictions and global demographic changes, among others.

"Consequently, we see enormous potential," its chief executive officer for Asia Pacific, Europe, the Middle East and Africa, and Germany, Alexander von zur Muehlen said.

Muehlen, who is also a member of the management board for the lender, said India is a critical growth market for it and the lender has boosted the capital allocation in India to enable expansion and further deepening its presence.

The bank affirmed its commitment to support India's growth, especially in areas such as digital transformation, sustainable finance, technology and infrastructure development.

Its country chief executive officer Kaushik Shaparia termed the infusion as a strong validation of confidence in the business model and potential in India.

The statement said the capital will be only for its branches in the country and excludes other entities operating in the country.

Deutsche Bank had infused Rs 2,700 crore of capital into India operations in 2020, and Rs 3,800 crore in 2019. In FY23, its profit after tax had declined marginally to Rs 1,467 crore, and the capital adequacy had stood at 15.41 per cent as of March 31, 2023.
Source: PTI
Read More On:
indiabankinginvestmentcapital infusiondeutsche bank
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

SBI MD: Concerns Over Account Aggregator Consent

SBI MD Ashwini Kumar Tewari raises concerns about Account Aggregator's single consent...

Silver Hits Record High on Fed Rate Cut Hopes

Silver futures soar to Rs 1.91 lakh/kg on Fed rate cut expectations. Gold rises. Market...

SpiceJet Adds 100 Daily Flights for Winter Demand

SpiceJet plans to add up to 100 daily flights this winter to meet growing demand and...

2 Lakh Startups Recognised by Govt: Startup India

Government recognizes over 2 lakh startups under Startup India. Incentives, job...

Waaree Energies: 1 GW Solar Module Output Record

Waaree Energies achieves record 1 GW monthly solar module output in November 2025, a...

India FTA Talks with Oman, New Zealand Nearing End

Piyush Goyal announces FTA negotiations with Oman, New Zealand in final stages. Trade...

Telangana to Launch Rs 1,000 Cr Startup Fund

Telangana CM announces Rs 1,000 crore startup fund to boost Hyderabad as a unicorn hub....

ADB Raises India GDP Growth Forecast to 7.2%...

ADB sharply revises India''s GDP growth forecast upward to 7.2% for FY26, driven by...

India, EU FTA Talks Progress: Goyal Comments

Piyush Goyal says India and EU are committed to early conclusion of FTA negotiations. A...

Zydus Launches Denosumab Biosimilar Zyrifa

Zydus Lifesciences launches Zyrifa, a Denosumab biosimilar for osteoporosis and...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com